AnteoTech Ltd (ASX: ADO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AnteoTech Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $61.61 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.46 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -33.33%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AnteoTech Ltd (ASX: ADO)
    Latest News

    Green arrow going up on stock market chart, symbolising a rising share price.
    Share Gainers

    Why Althea, AnteoTech, New Hope, and Omni Bridgeway shares are pushing higher

    These ASX shares are on form on Monday...

    Read more »

    Pilbara Minerals share price ASX lithium shares A stylised clean energy battery flexes its muscles, indicating a strong lift in share price for ASX energy companies
    Industrials Shares

    Anteotech share price surges 20% after passing first lithium battery hurdle

    AnteoTech shares are on fire on Monday morning...

    Read more »

    A young women pumps her fists in excitement after seeing some good news on her laptop.
    Share Gainers

    Why these 2 ASX All Ordinaries shares are surging more than 20% today

    Two ASX technology shares are leading the charge higher today.

    Read more »

    A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
    Healthcare Shares

    Why the AnteoTech share price is rocketing 33% today

    What did AnteoTech update the ASX with?

    Read more »

    Two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.
    Healthcare Shares

    Here's why the Anteotech (ASX:ADO) share price is leaping 6% today

    What news did this biotech company deliver today?

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    The AnteoTech (ASX:ADO) share price RAT-tles down 8% following TGA update

    The TGA has asked for more clinical data, so further trials will now be conducted.

    Read more »

    A bright graphic showing neon green and red arrows in a downwards direction with a world map behind them in neon blue
    Share Fallers

    Why AnteoTech, ASX, CIMIC, and Temple & Webster shares are dropping

    These ASX shares are falling on Thursday...

    Read more »

    Woman holding a rapid antigen test.
    Healthcare Shares

    Rats! How have AnteoTech (ASX:ADO) shares already gained 30% in February?

    AnteoTech is riding on the back of RATs in February...

    Read more »

    A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
    Coronavirus News

    Why are ASX COVID test shares climbing today?

    COVID-19 tests are in focus again today.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    AnteoTech (ASX:AD) share price surges 15% as COVID-19 RAT race continues

    The scientific company's shares have bounced back after a horror start to the week.

    Read more »

    man grimaces next to falling stock graph
    Healthcare Shares

    Why did the AnteoTech (ASX:ADO) share price tumble 13% on Monday

    AnteoTech shares have suffered in the past week.

    Read more »

    share price plummeting down
    Share Fallers

    Why Ansell, AnteoTech, Dubber, and NIB shares are dropping

    These ASX shares are in the red on Monday...

    Read more »

    Frequently Asked Questions

    No, AnteoTech does not pay dividends at this time.

    AnteoTech Ltd listed on the ASX on 7 April 2000.

    ADO ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AnteoTech Ltd

    AnteoTech Ltd (ASX: ADO) is a biotechnology company that uses its globally patented particle surface management technology to develop specialty products and services. The company's two key fields are end-user diagnostic products and battery technology.

    Its Life Sciences division is centred around AnteoBind, a product that connects biological and synthetic surfaces. The technology has various applications and also assists other diagnostic researchers in developing new products and medical devices.

    Meantime, the company's Energy division uses AnteoX binding technology to boost the performance of silicon-containing anodes delivering increased capacity, extended cycle life, and superior mechanical properties in lithium-ion batteries.

     

    ADO Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 May 2024 $0.02 $0.00 0.00% 20,875,315 $0.02 $0.03 $0.02
    21 May 2024 $0.02 $0.00 0.00% 2,765,061 $0.02 $0.02 $0.02
    20 May 2024 $0.02 $0.00 0.00% 1,224,884 $0.02 $0.02 $0.02
    17 May 2024 $0.02 $0.00 0.00% 316,006 $0.02 $0.02 $0.02
    16 May 2024 $0.02 $0.00 0.00% 732,872 $0.02 $0.02 $0.02
    15 May 2024 $0.02 $0.00 0.00% 242,391 $0.02 $0.02 $0.02
    14 May 2024 $0.02 $0.00 0.00% 221,687 $0.02 $0.02 $0.02
    13 May 2024 $0.02 $0.00 0.00% 122,583 $0.02 $0.02 $0.02
    10 May 2024 $0.02 $0.00 0.00% 5,253,389 $0.02 $0.02 $0.02
    09 May 2024 $0.02 $0.00 0.00% 973,480 $0.02 $0.02 $0.02
    08 May 2024 $0.02 $0.00 0.00% 2,762,110 $0.02 $0.02 $0.02
    07 May 2024 $0.02 $0.00 0.00% 1,547,985 $0.02 $0.02 $0.02
    06 May 2024 $0.02 $0.00 0.00% 1,692,540 $0.02 $0.02 $0.02
    03 May 2024 $0.02 $0.00 0.00% 1,731,512 $0.02 $0.02 $0.02
    02 May 2024 $0.02 $0.00 0.00% 3,199,738 $0.02 $0.02 $0.02
    01 May 2024 $0.02 $0.00 0.00% 6,655,854 $0.02 $0.02 $0.02
    30 Apr 2024 $0.02 $0.00 0.00% 972,727 $0.02 $0.02 $0.02
    29 Apr 2024 $0.02 $0.00 0.00% 7,331,265 $0.02 $0.02 $0.02
    26 Apr 2024 $0.02 $0.00 0.00% 1,734,045 $0.02 $0.02 $0.02
    24 Apr 2024 $0.02 $0.00 0.00% 99,301 $0.02 $0.02 $0.02
    23 Apr 2024 $0.02 $0.00 0.00% 459,136 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 Dec 2023 Geoffrey Cumming Expiry 1,500,000 $51,000
    Options expired.
    14 Nov 2023 Glenda McLoughlin Issued 468,750 $12,656
    Participation in share purchase plan.
    14 Nov 2023 Glenda McLoughlin Issued 1,500,000 $21,900
    Issue of options.
    14 Nov 2023 Katherine Woodthorpe Issued 1,500,000 $21,900
    Issue of options.
    14 Nov 2023 Geoffrey Cumming Issued 468,750 $12,656
    Participation in share purchase plan.
    14 Nov 2023 Geoffrey Cumming Issued 1,500,000 $21,900
    Issue of options.
    14 Nov 2023 David Radford Issued 10,000,000 $146,000
    Issue of options.
    14 Nov 2023 David Radford Issued 468,750 $12,656
    Participation in share purchase plan.
    14 Nov 2023 Ewen Crouch Issued 2,500,000 $36,500
    Issue of options.
    14 Nov 2023 Ewen Crouch Issued 468,750 $12,656
    Participation in share purchase plan.
    11 Sep 2023 Ewen Crouch Buy 937,500 $30,000
    Participation in share purchase plan.
    11 Sep 2023 Geoffrey Cumming Buy 937,500 $30,000
    Participation in share purchase plan.
    11 Sep 2023 David Radford Buy 937,500 $30,000
    Participation in share purchase plan.
    11 Sep 2023 Glenda McLoughlin Buy 937,500 $30,000
    Participation in share purchase plan.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Katherine Leslie Woodthorpe Non-Executive Director Sep 2021
    Dr Woodthorpe AO is an experienced Chair and Non-Executive Director serving for over 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has sat on the boards of a number of healthcare companies including Ventracor and Sirtex Ltd. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. He is also a Member of the Audit and Risk Committee and Member of the Energy Advisory Board.
    Dr Geoffrey James Cumming Non-Executive Director Apr 2009
    Dr Cumming has over 20 years' experience in the healthcare and biotechnology market. He was also Managing Director and CEO of Biosceptre Ltd. During his tenure he was responsible for taking research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. He is also a member of Risk Committee and Member of Clinical Advisory Board.
    Ms Glenda McLoughlin Non-Executive Director Sep 2021
    Ms McLoughlin is an experienced Chair and Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. He is also a Member of the Remuneration and Nomination Committee, Chair of the Audit and Risk Committee and Chair of the Energy Advisory Board.
    Mr Richard Shubrick Martin Non-Executive Director Sep 2005
    Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
    Mr David John Radford Chief Executive OfficerManaging Director Oct 2022
    Mr Radford is an internationally experienced CEO and Company Director with a track record of identifying and delivering profitable growth across a range of industries and geographies. He has direct experience in coordinating international teams, executing business turnarounds, product development and product launches, and operational initiatives to drive material growth in revenue and profits. He is a member of Risk Committee.
    Mr Ewen Graham Wolseley Crouch Non-Executive ChairmanNon-Executive Director Apr 2022
    Mr Crouch was a Partner at Allens from 1998 to 2013 where his roles included Chairman of Partners, Co-Head Mergers and Acquisitions and Equity Capital Markets, Executive Partner - Asian Offices and Deputy Managing Partner, as well as 11 years' service on its board. He served as a director of Mission Australia between 1995 and 2016, including 7 years as its Chairman. He is a Member of the Audit and Risk Committee.
    Mr Andrew Cook Company Secretary Aug 2023
    -
    Andrew Cook Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Levenson Investments Pty Ltd 95,932,718 4.41%
    Marcolongo Nominees Pty Ltd 55,634,380 2.56%
    First Cape Management Pty Ltd 55,195,509 2.54%
    Addison Lake Quality Hire Pty Limited 38,844,879 1.79%
    Fossil Super Pty Ltd 34,100,000 1.57%
    Bond Street Custodians Limited 24,130,249 1.11%
    Palm Beach Nominees Pty Limited 23,437,500 1.08%
    BNP Paribas Nominees Pty Ltd 23,114,127 1.06%
    Mr Peter Frederick Kemmis 22,385,655 1.03%
    Computer Visions Pty Ltd 22,132,994 1.02%
    Marcolongo Nominees Pty Ltd (ii) 21,897,938 1.01%
    Mcrae Superannuation Pty Ltd 20,125,000 0.93%
    Mrs Mary Curtis 19,617,450 0.90%
    Mr Anthony William Olding & Mrs Caroline Anne Olding 18,817,142 0.87%
    Bnp Paribas Noms Pty Ltd 18,175,529 0.84%
    AWO & CAO Investments Pty Ltd 17,497,856 0.80%
    Terry & Linden Deavin Super Pty Ltd 16,100,000 0.74%
    HSBC Custody Nominees (Australia) Limited 15,667,163 0.72%
    Mrs Elaine Janice Salisbury 15,400,000 0.71%
    Mr Richard Shubrick Martin & Mrs Fiona Diana Martin 14,862,514 0.68%

    Profile

    since

    Note